Keen Vision Acquisition Corporation is a blank check company formed under the laws of the British Virgin Islands on June 18, 2021, for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
Keen Vision Acquisition Corporation does not generate any…
Keen Vision Acquisition Corporation is a blank check company formed under the laws of the British Virgin Islands on June 18, 2021, for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
Keen Vision Acquisition Corporation does not generate any operating revenues as it has not yet completed its initial business combination. Its activity is limited to the evaluation of business combination candidates, and it incurs expenses related to being a public company, including legal, financial reporting, accounting, auditing compliance, and due diligence costs in connection with its search for a target business.
The company operates through the following segments: no_segments_reported
Keen Vision Acquisition Corporation operates in the highly competitive special purpose acquisition company (SPAC) industry, where numerous blank check companies seek to identify and merge with private operating businesses. Its competitive position is defined by its ability to complete a business combination within the required timeframe, the quality of its target selection, and the strength of its sponsor and management team in executing transactions. The company faces competition from other SPACs targeting similar sectors, particularly in the biopharmaceutical and healthcare spaces, as evidenced by its letter of intent with a Boston-based clinical stage biopharmaceutical company and subsequent merger agreement with Medera Inc.
Keen Vision Acquisition Corporation serves public shareholders who participated in its initial public offering and private placement. Its investor base includes institutional and retail investors who purchased units in the offering, each consisting of one ordinary share and one redeemable warrant. The company does not serve commercial customers or end-users of products or services, as it has no operational business prior to completing its initial business combination.